Home Forums Other Specialities Therapeutics RIVAROXABAN-TREATMENT OF DVT AND PULMONARY EMBOLISM

This topic contains 1 voice and has 0 replies.
1 voice
0 replies
  • Author
    Posts
  • #2820
    Anonymous
    Inactive

    Rivaroxaban (Xarelto, Bayer) is indicated for the ‘treatment of deep vein
    thrombosis and pulmonary embolism, and prevention of recurrent deep vein
    thrombosis and pulmonary embolism in adults’.

    For the initial treatment of
    acute pulmonary embolism, the recommended dosage of rivaroxaban is 15 mg
    twice daily for the first 21 days followed by 20 mg once daily for continued
    treatment and prevention of recurrent venous thromboembolism.

    Rivaroxaban for the treatment of deep vein thrombosis and prevention of
    recurrent deep vein thrombosis and pulmonary embolism (NICE
    guidance 261) recommends rivaroxaban as an option for treating
    deep vein thrombosis and preventing recurrent deep vein thrombosis and
    pulmonary embolism after a diagnosis of acute deep vein thrombosis in adults.

    The duration of treatment recommended in the summary of product
    characteristics depends on bleeding risk and other clinical criteria.
    Short-term
    treatment (at least 3 months) is recommended for people with transient risk
    factors such as recent surgery and trauma.

    Longer treatment is recommended
    for people with permanent risk factors, or idiopathic (unprovoked) deep vein
    thrombosis or pulmonary embolism.

    A reduced dosage of 15 mg twice daily for
    21 days followed by 15 mg once daily should be used in people with moderate
    (creatinine clearance 30–49 ml/min) or severe (creatinine clearance 15–29 ml/
    min) renal impairment if their risk of bleeding outweighs the risk of recurrent
    deep vein thrombosis or pulmonary embolism.

    The summary of product characteristics lists the following adverse reactions for
    rivaroxaban: anaemia, dizziness, headache, fainting, bleeding events,
    tachycardia (rapid heartbeat), low blood pressure, haematoma, stomach pain,
    dyspepsia (heartburn), nausea, constipation, diarrhoea, vomiting, pruritus
    (itching), rash, bruising, pain in the extremities, fever, and swelling, especially
    of the ankles and feet.

    For full details of side effects and contraindications, see
    the summary of product characteristics.

    National Institute of Clinical Excellence-UK.

    G Mohan.

You must be logged in to reply to this topic.